Rosetta Genomics Announces Next-Generation Sequencing

PRINCETON, NJ and REHOVOT, ISRAEL--(Marketwired - Jul 29, 2014) - Rosetta Genomics Ltd. ( NASDAQ : ROSG ), a leading developer and provider of microRNA-based molecular diagnostics, announces that the Company has entered into a collaborative research and license agreement with Yeda Research and Development Co. Ltd., the commercial arm of the Weizmann Institute of Science. The agreement involves collaboration with the Nancy and Stephen Grand Israel National Center for Personalized Medicine to develop novel methods for the preparation of next-generation sequencing libraries for small RNAs. The initial goals of this collaboration are to make this type of sequencing more cost effective as well as to minimize sequence-specific biases. The collaboration also aims at developing computational methods required for data analysis. The potential developed methods could allow more accurate quantification of microRNAs in various biological samples and pathological conditions.

"We are very pleased to be working with the Weizmann Institute of Science on these important programs. The Weizmann Institute is one of the world's leading multidisciplinary research institutes, and the source of numerous groundbreaking medical discoveries and technological applications. Working in collaboration with the Institute provides us with the world-class infrastructure needed to pursue breakthroughs in sequencing and data analysis," stated Kenneth A. Berlin, Rosetta President and Chief Executive Officer. "The major advantages of next-generation sequencing for microRNA profiling are detection of both novel and known microRNAs and precise identification of microRNA sequences. These advances will allow us to incorporate sequencing in more of our projects, thereby enhancing our capabilities to more cost-effectively and accurately develop powerful, new diagnostic products with significant clinical utility."

About Rosetta Cancer Testing Services Rosetta Cancer Tests are a series of microRNA-based diagnostic testing services offered by Rosetta Genomics. The Rosetta Cancer Origin Test ^™ can accurately identify the primary tumor type in primary and metastatic cancer, including cancer of unknown or uncertain primary (CUP). Rosetta Mesothelioma Test ^™ diagnoses mesothelioma, a cancer connected to asbestos exposure. The Rosetta Lung Cancer Test ^™ accurately identifies the four main subtypes of lung cancer, using small amounts of tumor cells. The Rosetta Kidney Cancer Test ^™ accurately classifies the four most common kidney tumors: clear cell renal cell carcinoma (RCC), papillary RCC, chromophobe RCC and oncocytoma. Rosetta's assays are designed to provide objective diagnostic data; it is the treating physician's responsibility to diagnose and administer the appropriate treatment. Rosetta Genomics estimates that, in the U.S. alone, 200,000 patients a year may benefit from the Rosetta Cancer Origin Test ^™ , 60,000 from the Rosetta Mesothelioma Test ^™ , 65,000 from the Rosetta Kidney Cancer Test™ and 226,000 patients from the Rosetta Lung Cancer Test ^™ . The Company's assays are offered directly by Rosetta Genomics in the U.S. and, through distributors, around the world. For more information, please visit www.rosettagenomics.com . Parties interested in ordering the test can contact Rosetta Genomics at -215-382-9000 ext. 309.

About the Weizmann Institute of Science The Weizmann Institute of Science in Rehovot, Israel, is one of the world's top-ranking multidisciplinary research institutions. Noted for its wide-ranging exploration of the natural and exact sciences, the Institute is home to scientists, students, technicians and supporting staff. Institute research efforts include searching for new ways of fighting disease and hunger, examining leading questions in mathematics and computer science, probing the physics of matter and the universe, creating novel materials and developing new environmental protection strategies.

About the Nancy and Stephen Grand Israel National Center for Personalized Medicine Established in 2013 by the Weizmann Institute of Science, the Nancy and Stephen Grand Israel National Center for Personalized Medicine is an advanced research facility that offers academic, medical, and biomedical industry researchers access to state-of-the-art genomics, proteomics, high-throughput screening of small molecules and bioinformatics research platforms. The Center is comprised of four scientific units working together: the Crown Institute for Genomics, the de Botton Institute for Protein Profiling, the Maurice and Vivienne Wohl Institute for Drug Discovery and the Ilana and Pascal Mantoux Institute for Bioinformatics. Under the Center's auspices, multidisciplinary teams of experts from the various fields are creating and implementing the research tools and technologies of the future and adapting cutting-edge methods developed in Weizmann Institute laboratories and elsewhere for broad usage. The Center is located on campus in a building that is currently being renovated with the support of the Wolfson Family Foundation and the Wolfson Family Charitable Trust.

About Rosetta Genomics Founded in 2000, Rosetta's integrative research platform combining bioinformatics and state-of- the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools and therapeutics. Rosetta currently commercializes a full range of microRNA-based molecular diagnostics. Rosetta's cancer testing services are commercially available through its Philadelphia-based CAP-accredited, CLIA-certified lab. For more information please visit www.rosettagenomics.com .

Forward-Looking Statement Disclaimer Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, Rosetta's Cancer of Origin Test™, Rosetta's development or commercialization of molecular diagnostics, novel methods for the preparation of next-generation sequencing libraries or computational methods required for data analysis and Rosetta's development of personalized medicine products and services, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2012, as filed with the SEC. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.